Striatal Connectivity and Clinical Outcome in Psychosis
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
This is an observational neuroimaging treatment study. This study involves examining the
neural circuitry of controlled treatment of patients presenting with a first-episode of
psychosis with risperidone or aripiprazole. Patients who present for treatment of a first
psychotic episode with a schizophrenia spectrum diagnosis and who are eligible to undergo
treatment with either risperidone or aripiprazole will be offered participation in the study.
Clinical ratings, neuropsychological testing, neuroimaging and EEG will be conducted at
baseline. Additionally, subjects will undergo the same assessments at week 12 to determine
treatment-related biomarkers. Clinical ratings, including neurocognitive testing, will be
conducted by blinded raters at study visits during treatment. Healthy controls (N=50) will
also be recruited and scanned twice (12-week interval) to control for effects of time and
practice.